LGALS1 and myeloid neoplasm: Ongoing work will be aimed at determining the mechanisms of action for galectin-1 in myeloid neoplasms, further validating the efficacy of galectin-1 targeting in additional disease models, and identifying the most clinically-tractable targeting modality.